Login
Navigate Fool.com
Will AMGN beat
the market?

Amgen, Inc. (NASDAQ: AMGN)

Community Rating: 4 Stars: Favorite

119.03 0.00 (0.00%)

REAL-TIME: Last trade at

Extended Hours: $119.05 $0.02 (0.02%)
Quote as of (NASDAQ)


company name or ticker

Recent Quotes

Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $117.63
Previous Close $119.03
Daily Range $117.20 - $119.34
52-Week Range $103.31 - $128.96
Market Cap $90.1B
P/E Ratio 19.20
Dividend (Yield) $2.44 (2.1%)
Ex-Dividend Date
Dividend Pay Date
05/13/14
06/06/14
Volume 3,076,630
Average Daily Volume 2,618,823
Current FY EPS $8.10

How do you think AMGN
will perform against the market?

Top AMGN Bull/Bear Pitches

 

SoftDad (0)
Submitted June 18, 2013

Amgen has a great pipeline of lifesaving biologic therapies. It has a proven track record of bringing highly innovative and effective drugs to market.

0 Replies Reply Report this Post
 

bclan13 (< 20)
Submitted February 5, 2013

I don't see anything replacing the big supportive care indications, which will probably get cut in half in coming years by a combination of biosimilars and increasing price sensitivity by numerous gov … More

0 Replies Reply Report this Post

News & Commentary Rss Feed

Yellen Hates Biotech Stocks! Should You?

Are big biotechs -- Amgen, Biogen Idec, Gilead Sciences, and Celgene -- really overvalued, or is the Fed chairwoman looking at smaller companies?

Notable ETF Inflow Detected - IWB, AMGN, UNH, BMY

Deutsche Bank Raises Price Targets on Top Biotech and Health Care Stocks

This Week in Biotech: AbbVie's Five-Leaf Clover and Exelixis' Excellent Results

A long-awaited mega-merger is announced, Exelixis reminds Wall Street that its pipeline is more than a single compound, and Amgen shows flashes of what's coming down its pipeline.

Will Incoming Competition Derail Aegerion Stock?

A new class of cholesterol drugs including Amgen's (AMGN) evolocumab could soon be competing for Aegerion's (AEGR) market share in HoFH patients.

4 Top Biotechs Expected to Beat Earnings Expectations

Fed: Beware of social media, biotech stocks

UBS Very Bullish on Biotech Stocks Ahead of Second-Quarter Earnings

Alexion Pharma Looks To Life Beyond Its Blockbuster

Sector Update: Healthcare Stocks Slightly Higher; BIND Therapeutics Drops Partnership with Amgen on

Sector Update: Healthcare Stocks Slightly Higher; BIND Therapeutics Drops Partnership with Amgen on Cancer Treatment

See More AMGN News...

Sector

Healthcare

Industry

Drugs

Amgen, Inc. (AMGN) Description

A biotechnology company which discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology. Website: http://www.amgen.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks